ClinicalTrials.gg
Active, not recruitingNCT06122779AURORA-HFpEFUpdated Jul 30, 2026

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

A Phase 2 interventional study of BMS-986435 and Placebo in Heart Failure, sponsored by Bristol-Myers Squibb. Active, not recruiting at 86 sites in 11 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Heart Failure by Bristol-Myers Squibb — 1 open to participants now, 2 under way, none of them phase 3. Heart Failure · Bristol-Myers Squibb.

Enrollment
3rd of 20
227 · median 54
Started
2023
with 1 other
Phase 2
7 of 28
none open now
Registered
28th of 28
by date

Among the 28 studies in Heart Failure by Bristol-Myers Squibb, this one is the 3rd largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 2, and was the 28th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 28 studies in Heart Failure by Bristol-Myers Squibb is open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Heart Failure by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • BMS-986435
  • MYK-224
  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • HFpEF
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.

Exclusion criteria

Exclusion Criteria

  • Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
227 participants (actual)

Study arms

  • Experimental
    BMS-986435

    Drug: BMS-986435

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: MYK-224

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Up to approximately 24 weeks

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to approximately 24 weeks

  3. Incidence of AEs leading to treatment discontinuation

    Time frame: Up to approximately 20 weeks

Secondary outcomes

  1. Summary of plasma concentrations of MYK-224

    Time frame: Up to approximately 20 weeks

07

Study locations

86 sites
  • Local Institution - 0002
    Birmingham, Alabama 35233, United States
  • Local Institution - 0096
    Lakewood, Colorado 80228-1710, United States
  • Local Institution - 0077
    Jacksonville, Florida 32204-4748, United States
  • Local Institution - 0003
    Miami, Florida 33133-4223, United States
  • Local Institution - 0099
    Miami, Florida 33136-2107, United States
  • Local Institution - 0004
    Chicago, Illinois 60611-5969, United States
  • Local Institution - 0005
    Hazel Crest, Illinois 60429-2196, United States
  • Local Institution - 0029
    Indianapolis, Indiana 46260-1992, United States
  • Local Institution - 0028
    St Louis, Missouri 63136-6111, United States
  • Local Institution - 0117
    Hackensack, New Jersey 07601-1915, United States
  • Local Institution - 0070
    Albany, New York 12211, United States
  • Local Institution - 0105
    Brooklyn, New York 11215, United States
  • Local Institution - 0008
    New York, New York 10065-4805, United States
  • Local Institution - 0059
    Rochester, New York 14618-2668, United States
  • Local Institution - 0076
    Rochester, New York 14621, United States
  • Local Institution - 0094
    Rosedale, New York 11422-1320, United States
  • Local Institution - 0095
    Durham, North Carolina 27710-4000, United States
  • Local Institution - 0016
    Oklahoma City, Oklahoma 73135-2607, United States
  • Local Institution - 0078
    Abington, Pennsylvania 19001, United States
  • Local Institution - 0001
    Tullahoma, Tennessee 37388-8260, United States
  • Local Institution - 0104
    Austin, Texas 78756-4080, United States
  • Local Institution - 0036
    Dallas, Texas 75390, United States
  • Local Institution - 0015
    Houston, Texas 77025-5253, United States
  • Local Institution - 0054
    Ciudad del Libertador General San Martin, Buenos Aires B1650BNB, Argentina
  • Local Institution - 0115
    Zárate, Buenos Aires B2800DGH, Argentina
  • Local Institution - 0090
    Córdoba, Córdoba Province 5000, Argentina
  • Local Institution - 0053
    Córdoba, Córdoba Province X5003DCE, Argentina
  • Local Institution - 0073
    Rosario, Santa Fe Province 2000, Argentina
  • Local Institution - 0061
    San Miguel de Tucumán, Tucumán Province T4000IAP, Argentina
  • Local Institution - 0060
    Buenos Aires, 1407, Argentina
  • Local Institution - 0067
    Buenos Aires, C1431FWO, Argentina
  • Local Institution - 0074
    Córdoba, X5000AOQ, Argentina
  • Local Institution - 0069
    Salta, A4406BPF, Argentina
  • Local Institution - 0102
    Santa Fe, S3000FWO, Argentina
  • Local Institution - 0007
    Hamilton, Ontario L8L 2X2, Canada
  • Local Institution - 0037
    Toronto, Ontario M4P 1E4, Canada
  • Local Institution - 0089
    Beijing, Beijing Municipality 100730, China
  • Local Institution - 0087
    Guangzhou, Guangdong 510120, China
  • Local Institution - 0080
    Luoyang, Henan 471003, China
  • Local Institution - 0079
    Changsha, Hunan 410011, China
  • Local Institution - 0082
    Hangzhou, Zhejiang 310009, China
  • Local Institution - 0109
    Jerusalem, Jerusalem 90000, Israel
  • Local Institution - 0111
    Beersheba, 84101, Israel
  • Local Institution - 0112
    Be’er Ya‘aqov, 7033001, Israel
  • Local Institution - 0108
    Haifa, 3109601, Israel
  • Local Institution - 0113
    Jerusalem, 9103102, Israel
  • Local Institution - 0110
    Petah Tikva, 49100, Israel
  • Local Institution - 0106
    Rehovot, 76100, Israel
  • Local Institution - 0116
    Safed, 1311001, Israel
  • Local Institution - 0019
    Naples, Campania 80131, Italy
  • Local Institution - 0022
    San Donato Milanese, Lombardy 20097, Italy
  • Local Institution - 0017
    Pisa, Tuscany 56126, Italy
  • Local Institution - 0009
    Bergamo, 24127, Italy
  • Local Institution - 0092
    Himeji-Shi, Hyōgo 672-8044, Japan
  • Local Institution - 0100
    Kanazawa, Ishikawa-ken 920-8650, Japan
  • Local Institution - 0091
    Okayama, Okayama-ken 702-8055, Japan
  • Local Institution - 0093
    Kishiwada, Osaka 596-0042, Japan
  • Local Institution - 0103
    Takatsuki-Shi, Osaka 569-1045, Japan
  • Local Institution - 0013
    Lódz, Lódzkie 92-213, Poland
  • Local Institution - 0031
    Bialystok, Podlaskie Voivodeship 15-276, Poland
  • Local Institution - 0086
    Pusan, Busan Gwangyeogsi 49241, South Korea
  • Local Institution - 0084
    Daejeon, Daejeon Gwang'yeogsi 35015, South Korea
  • Local Institution - 0083
    Gwangju, Gwangju Gwang'yeogsi 61469, South Korea
  • Local Institution - 0098
    Seongnam, Gyeonggido 13620, South Korea
  • Local Institution - 0056
    Junggu, Incheon Gwang'yeogsi 22332, South Korea
  • Local Institution - 0081
    Seoul, Seoul Teugbyeolsi 03080, South Korea
  • Local Institution - 0085
    Seoul, Seoul Teugbyeolsi 03722, South Korea
  • Local Institution - 0114
    Seoul, Seoul Teugbyeolsi 06351, South Korea
  • Local Institution - 0055
    Seoul, Seoul Teugbyeolsi 06591, South Korea
  • Local Institution - 0088
    Daegu, 42601, South Korea
  • Local Institution - 0012
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Local Institution - 0025
    Majadahonda, Madrid 28222, Spain
  • Local Institution - 0021
    El Palmar, Murcia 30120, Spain
  • Local Institution - 0026
    Madrid, 28034, Spain
  • Local Institution - 0032
    Málaga, 29010, Spain
  • Local Institution - 0018
    Seville, 41014, Spain
  • Local Institution - 0010
    Valencia, 46010, Spain
  • Local Institution - 0063
    Harrow, Greater London HA1 3UJ, United Kingdom
  • Local Institution - 0071
    North Shields, Northumberland NE29 8NH, United Kingdom
  • Local Institution - 0072
    Leeds, Yorkshire LS1 3EX, United Kingdom
  • Local Institution - 0101
    Bristol, BS2 8HW, United Kingdom
  • Local Institution - 0097
    Dundee, DD1 9SY, United Kingdom
  • Local Institution - 0075
    London, SE1 7EH, United Kingdom
  • Local Institution - 0062
    Oxford, OX3 9DU, United Kingdom
  • Local Institution - 0065
    Stockton-on-Tees, TS19 8PE, United Kingdom
  • Local Institution - 0064
    Wolverhampton, WV10 0QP, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Dec 2026, 37 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 37 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 8, 2023
StartActual
Nov 7, 2023
Primary completionEst.
Dec 14, 2026
CompletionEst.
Dec 14, 2026
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06122779
Responsible party
Sponsor
First posted
Nov 8, 2023
Start date
Nov 7, 2023
Primary completion
Dec 14, 2026 (estimated)
Completion
Dec 14, 2026 (estimated)
Last update
Jul 30, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delocamten

Start the discussion